We are live on ! Find out more
ATXS

Astria Therapeutics

Delisted

ATXS was delisted on the 22nd of January, 2026.

28 hedge funds and large institutions have $31.3M invested in Astria Therapeutics in 2019 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

33% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 6

31% more capital invested

Capital invested by funds: $23.9M → $31.3M (+$7.42M)

29% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 7

8% more funds holding

Funds holding: 2628 (+2)

1.13% more ownership

Funds ownership: 6.34%7.48% (+1.1%)

Holders
28
Holders Change
+2
Holders Change %
+7.69%
% of All Funds
0.55%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
9
Increased
8
Reduced
6
Closed
7
Calls
$6.65M
Puts
Net Calls
+$6.65M
Net Calls Change
+$574K

ATXS Hedge Fund Activity: Q4 2019 in Review

28 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q4 2019, worth a combined $31.3M — up 31% from $23.9M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new ATXS positions and 7 closed out — a net gain of 2 holders — while 8 added to existing stakes and 6 trimmed.

The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $659K. The largest seller was Federated Hermes, cutting an estimated $350K.

  • 28 institutional investors held Astria Therapeutics (ATXS) as of Q4 2019, up from 26 in Q3 2019.
  • Funds reported $31.3M of Astria Therapeutics stock for Q4 2019, up 31% quarter-over-quarter.
  • 9 funds opened new Astria Therapeutics positions in Q4 2019 and 7 closed out, a net change of +2 holders.
  • The largest Astria Therapeutics buyer in Q4 2019 was Alyeska Investment Group, an estimated $659K added.
  • The largest Astria Therapeutics seller in Q4 2019 was Federated Hermes, an estimated $350K sold.

Based on aggregated 13F filings for Q4 2019.